Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 767.62

-3.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (90)	5/3/1997 2:36:00 PM
From: scaram(o)uche	of 3559

Miljenko..... thanks. While you misunderstood my TKTX reference, you partly answered my question (re. CTII) elsewhere. TKTX and AMGN are enemies, both in lab and court, not collaborators. When I referred to a "work around", I was asking if CTII had a means to work around REGN/AMGN patents as TKTX claims to have for epo patents at AMGN. I don't understand your question relating to ArQule. OK, taking your observation of the CTII comments one step further, would they discontinue development of BDNF to avoid license payments to REGN/AMGN, or do they simply not have rights to the molecule? Is it clear that they would NEED a license (that's what I was trying to get at with the "work around" question)? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next